IJERPH, Vol. 18, Pages 10081: Public Knowledge, Attitude, and Perception towards COVID-19 Vaccination in Saudi Arabia

This study is a cross-sectional, web-based online survey conducted using a snowball sampling technique. A self-administered questionnaire prepared in Arabic and English was used to collect feedback from the general population on their knowledge, attitudes, and perceptions about the COVID-19 vaccine. Participants (n = 2022) from different regions of the country replied to the questions. The responses to the questions were recorded on a spreadsheet and analyzed using the SPSS software. Statistical analysis was performed using one-way ANOVA and non-parametric tests to draw conclusions about the results. Multivariate stepwise regression analysis was performed to determine the association between the knowledge, attitude, and perception scores and the demographic variables. p < 0.05 was used to indicate the significance of the data. The data from the study indicated that most of the participants were males (81%), between 18 and 59 years of age (85.9%), Saudi nationals (98.3%), and possessed graduation or above as a qualification (62.9%). The results suggest that a major portion of respondents have satisfactory knowledge (76%), a positive attitude (72.4%), and perception (71.3%) towards the use of COVID-19 vaccines. Their responses can be categorized as between ‘good’ and ‘fair’. However, 30–40% of respondents lacked information about COVID-19 vaccination availability for under 18-year-olds as well as for pregnant women, in addition to the lack o...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research

Related Links:

NEW BRUNSWICK, N.J., October 15, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson &J...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
We report an updated literature review of current information and evidence available to aid in the decision whether to vaccinate against COVID-19 currently being made by pregnant individuals and their healthcare providers so that they are able to make a well-informed recommendation and decision.PMID:34651406 | DOI:10.1111/1471-0528.16973
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research
Bull World Health Organ. 2021 Oct 1;99(10):739-746. doi: 10.2471/BLT.21.286644. Epub 2021 Aug 30.ABSTRACTThe rapid development and roll-out of coronavirus disease 2019 (COVID-19) vaccines is providing hope for a way to control the pandemic. As pregnant and lactating women are generally excluded from clinical trials, the vaccination programme was launched without adequate safety and efficacy data for pregnant women. Yet many professional organizations have recognized the need for administration of COVID-19 vaccines in pregnancy and have issued their own set of recommendations. The lack of evidence, however, has often led to...
Source: Bulletin of the World Health Organization - Category: International Medicine & Public Health Authors: Source Type: research
NEW BRUNSWICK, N.J., October 05, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson &Johnson COVID-19 vaccine in individuals 18 years of age and older.The submission includes recent results from the Phase 3 ENSEMBLE 2 study that found a booster of the Johnson &Johnson COVID-19 vaccine given 56 days after the primary dose provided 94 percent protection against symptomatic (moderate to severe/critical) COVID-19 in the U.S. (CI, 58%-100%) and 100 percent protection (CI, 33%-100%) agai...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety,...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
In conclusion an individualized approach should be provided by a multidisciplinary team for the management of pregnant women with COVID-19 to achieve favorable outcomes.PMID:34536988 | DOI:10.3906/sag-2106-134
Source: Turkish Journal of Medical Sciences - Category: General Medicine Authors: Source Type: research
Purpose of review : The Coronavirus Disease 2019 (COVID-19) pandemic has had an unprecedented impact on pregnant women, maternity services and healthcare workers. We review recent literature on the course of COVID-19 infection in pregnancy, and recommendations for treatment and service provision. Recent findings It has been increasingly recognised that pregnant women are at higher risk of severe disease associated with COVID-19 infection. Early critical care input is crucial to guide respiratory support and techniques such as prone positioning, with a low threshold for intubation in critical illness. Timing of d...
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: WOMEN’S HEALTH: Edited by Joseph Aquilina Source Type: research
Biochim Biophys Acta Mol Basis Dis. 2021 Sep 2;1867(12):166264. doi: 10.1016/j.bbadis.2021.166264. Online ahead of print.ABSTRACTThe molecular evolution of life on earth along with changing environmental, conditions has rendered mankind susceptible to endemic and pandemic emerging infectious diseases. The effects of certain systemic viral and bacterial infections on morbidity and mortality are considered as examples of recent emerging infections. Here we will focus on three examples of infections that are important in pregnancy and early childhood: SARS-CoV-2 virus, Zika virus, and Mycoplasma species. The basic structural ...
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Source Type: research
Ian Harvey urges the JCVI to vaccinate teenagers as schools return from the summer break, andAusten Lynch says the Covid death toll is still highScientific advice to the government has mostly been good during the pandemic, but the Joint Committee on Vaccination and Immunisation (JCVI) is showing unhelpful signs of procrastination over the vaccination of teenagers and the use of adult boosters (Report, 27 August). It is also playing out its discussion via the media rather than in a timely fashion in private. Its doubts about vaccinating teenagers are said to centre on concerns about side-effects, the ethics of indirect bene...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus Infectious diseases Science Vaccines and immunisation Source Type: news
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson &Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson &Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson &Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals pr...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Children | Coronavirus | COVID-19 | Environmental Health | Graduation | International Medicine & Public Health | Middle East Health | Pandemics | Pregnancy | Respiratory Medicine | Saudi Arabia Health | Statistics | Study | Vaccines | Women